Physician profile
Suzanne Lee Don
NPI 1992914154
$118,613.07
in general payments reported to CMS, 2019-2025
7 companies · $38K in 2025
The $38K reported for 2025 was more than what 99% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $9,298 · 2021: $20K · 2022: $2,703 · 2023: $18K · 2024: $15K · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $34K · Honoraria: $30K · Travel and Lodging: $4,425 · Food and Beverage: $2,889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $33,885.00 |
| Honoraria | $30,038.00 |
| Travel and Lodging | $4,424.88 |
| Food and Beverage | $2,888.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $67,500.41 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $42,752.09 | 2019-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $7,385.95 | 2025 | Jornay Pm |
| Tris Pharma INC | $424.55 | 2019-2023 | Dyanavel Xr |
| Corium, LLC | $364.91 | 2022-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $108.87 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $76.29 | 2024 | Rexulti, Rejoyn |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Don listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.